Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Acquisitions & Divestments (2023 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 10.42% to $9.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $59.1 million, a 44.48% decrease, with the full-year FY2024 number at $86.6 million, down 43.31% from a year prior.
  • Change in Acquisitions & Divestments was $9.5 million for Q3 2025 at Orchestra BioMed Holdings, down from $16.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $51.5 million in Q3 2023 to a low of $9.5 million in Q3 2025.
  • A 3-year average of $24.1 million and a median of $17.2 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 79.39% in 2024, then decreased 10.42% in 2025.
  • Orchestra BioMed Holdings' Change in Acquisitions & Divestments stood at $37.1 million in 2023, then plummeted by 53.57% to $17.2 million in 2024, then plummeted by 44.81% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Change in Acquisitions & Divestments are $9.5 million (Q3 2025), $16.4 million (Q2 2025), and $16.0 million (Q1 2025).